This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Amniotic Epithelial Cells
DrugBank Accession Number
DB15868
Background

Amniotic epithelial cells (AEC) are multipotent stem-like cells derived from the basement collagenous membrane of the human amnion, the layer of the placenta closest to the fetus.1,2 These cells are potential candidates for allogeneic cell therapy and regenerative medicine due to their potential for differentiation and multiplication.1

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • hAECs
  • Human Amniotic Epithelial Cells
External IDs
  • Amniotic Epithelial Cells

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Amniotic epithelial cells have immunosuppression properties, the likely reason why these cells seem to be resistant to rejection after allotransplantation. Further therapeutic effects of these cells include reported neuroprotection and neuroregeneration properties, attributed to the growth factor secretion by AECs. These cells are being investigated as a therapy against many different conditions, some of which include lung fibrosis, liver fibrosis, multiple sclerosis, congenital metabolic disorders, familial hypercholesterolemia, spinal cord injuries, ophthalmic diseases, and Parkinson’s disease.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Yang PJ, Yuan WX, Liu J, Li JY, Tan B, Qiu C, Zhu XL, Qiu C, Lai DM, Guo LH, Yu LY: Biological characterization of human amniotic epithelial cells in a serum-free system and their safety evaluation. Acta Pharmacol Sin. 2018 Aug;39(8):1305-1316. doi: 10.1038/aps.2018.22. Epub 2018 Mar 22. [Article]
  2. Atala A., Lanza R., Mikos T., and Nerem R. (2019). Principles of Regenerative Medicine (3rd ed.). Elsevier. [ISBN:9780128098936]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentAsherman's Syndrome1
1RecruitingTreatmentInfertility / Ovarian Insufficiency, Primary / Premature Ovarian Failure (POF)1
1Unknown StatusTreatmentHTLV-1 Associated Myelopathy1
1Unknown StatusTreatmentSpastic Cerebral Palsy (sCP)1
1, 2Not Yet RecruitingTreatmentNon-union of Fractures1
Not AvailableRecruitingPreventionAcute Graft-Versus-Host Disease (GVHD)1
Not AvailableUnknown StatusTreatmentPremature Ovarian Failure (POF)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 21, 2020 15:44 / Updated at September 22, 2020 13:00